-
Recent Posts
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
- Timeless Good Advice? (Action for Happiness)
- The Diversionary Value of Music Playlists for Patients With Dementia in Accident and Emergency Settings (Nurses.co.uk / BBC News)
- More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)
Archives
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Alzheimer’s Research UK’s Drug Discovery Alliance
Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK (ARUK) have released a brief report on six research priorities, which are: Achieving earlier detection of diseases which may cause dementia, (ideally by 10-15 years), to enhance development of new treatments / interventions for people most … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Accelerating Detection of Disease, Accelerating Detection of Disease (ADD) Challenge, Accelerating Detection of Disease Programme, Alzheimer's and Dementia: Translational Research and Clinical Interventions (TRCI), Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Dementia Attitudes Monitor, Alzheimer’s Research UK’s Drug Discovery Alliance, Awareness, Awareness Raising, Benefits of Detection and Early Intervention, Benefits of Early Detection, Biomarker Development, Biomarkers, Brain Health Clinics, Charity Research Support Fund, Cognitive Function and Ageing Study II, Cross-Funder Review, Dementia Access Taskforce, Dementia Consortium, Dementia Moonshot, Dementia Prevalence, Dementia Prevention, Dementia Research, Dementia Research and Drug Development, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia Translational Medicines Accelerator, Dementia: Prevalence and Detection, Dementias Platform UK, DPUK: Dementias Platform UK, Dr Helen Beaumont: Alzheimer’s Research UK Champion, Drug Development for Alzheimer's Disease, Drug Discovery Alliance, Drug Discovery Institutes, Drug Target Validation, Early Detection of Neurodegenerative Diseases, Economic Impact of Dementia, Global Impact of Dementia, Global Leadership, Government Research Funding, Grand Challenge on Artificial Intelligence and Data, Helen Stokes-Lampard: Chair of RCGP, Hilary Evans: Chief Executive of Alzheimer’s Research UK, Impact of Dementia, Impact of Dementia (Statistics), Impact of Dementia in UK, Life Sciences Industrial Strategy, Life-Changing Treatment for Dementia by 2025 (Moonshot Aim), Medical Research Charities, Mike Gooley Trailfinders Charity Prevention and Risk Reduction Fund, Modifiable Risk Factors, Multi-Morbidities, Multi-Morbidity, No Time to Lose: An Action Plan for Dementia (ARUK), Participation in Research, Patient Involvement in Research, Potential Drug Targets, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Professor Jamie Waterall: National Lead for Cardiovascular Disease at Public Health England, Professor Tara Spires-Jones: Alzheimer’s Research UK Grant Review Board, Research Funding, Research Priorities and Funding / Costs, Research Priorities and Networks, Social and Economic Impact of Dementia, Social and Economic Impact of Dementia in UK, Target Robustness Programme, Translational Medicines, Translational Research, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Health Research Funding
|
Leave a comment
New Drugs for Dementia (POST Note PN 535)
Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program
|
Leave a comment
Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)
Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute
|
Leave a comment
UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)
Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, For Researchers (mostly), In the News, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Research UK’s Drug Discovery Alliance, Big Pharma, Cambridge Biomedical Campus, Cambridge Drug Discovery Institute, Cambridge University, Clinical Research Networks, Collaborative Drug Discovery Programmes, Commissioning Research, Crowd-Sourced Information, Crowdsourcing, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Dr Laura Phipps: Alzheimer’s Research UK, Drug Discovery Alliance, Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, International Collaborations, International Organisations, International Programmes, Knowledge Networks, Knowledge Translation, Medical Research, MIT Sloan School of Management: Model for Public-Private Partnerships in Funding Research, Multidisciplinary Research Teams, Networks, Networks and Alliances, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Oxford Drug Discovery Institute, Oxford University, Parallel Discovery of Alzheimer’s Therapeutics (MIT Sloan and University of California Model), Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmacological Research, Philanthropic Funding, Philanthropy, Prof. David Rubinsztein: Lead Academic Scientist at Cambridge Drug Discovery Institute, Prof. Giampietro Schiavo: Co-Lead Academic Scientist at UCL Drug Discovery Institute, Prof; Simon Lovestone: Co-Lead Academic Scientists at Oxford Drug Discovery Institute, Research Commitment, Research Consortia, Research Culture, Research Mapping, Research Networks, Research Programmes, Scientific Management Board of the Drug Discovery Institute, Stem Cell Research, Translational Research, UCL Drug Discovery Institute, University College London (UCL), University of Cambridge, University of Oxford
|
Leave a comment
